This event was presented as a live webinar on December 10, 2015
CPEU Hours: 1.5
CPE Level: 2
Over the past 15 years advances in diabetes medicines and treatments have sky rocketed. Scientist have identified several new classes of diabetes medications allowing us to more effectively target the pathology associated with diabetes. More recently the U.S. Food and Drug Administration approved a new class of medications called sodium glucose limiting co-transporter 2 inhibitors (SGLT2) that target the kidney as a means of glycemic control. In the last three years, four new medications - including an injectable, where approved for the management of obesity in people with type 2 diabetes. And in 2013 the American Diabetes Association issued an updated position statement with new nutrition recommendations for the management of adults with diabetes. This rapid pace of research into new medications and nutrition intervention strategies for the management of diabetes, can be challenging for nutrition professionals and diabetes educators, who desire to educate their patients on the most accurate, up-to-date, evidence-based information.
At the end of this webinar participants will be able to:
- Discuss the mechanism of action, indication, efficacy, safety, adverse reactions and contraindications of SGLT2 inhibitors, and anti-obesity drugs.
- Educate patients and other healthcare professionals on the effectiveness of the following diets for people with diabetes; Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and plant-based (vegan or vegetarian), low fat, and low carbohydrate.
- Advise patients on the most appropriate weight loss pharmacotherapy according to their individual lifestyles, adherence problem and diet.
Please note: Webinar recording and information will be sent via the Professional Development's Hightail account in 48-72 business hours.